TOP TEN perturbations for 4541 (Homo sapiens)

Organism: Homo sapiens
Gene: 4541
Selected probe(set): 1553575_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 4541 (1553575_at) across 5339 perturbations tested by GENEVESTIGATOR:

ARC study 1 / untreated MCF-7 cell sample

Relative Expression (log2-ratio):5.5587606
Number of Samples:2 / 2
Experimental ARC study 1
MCF7 cells treated with 2uM ARC (4-amino-6-hydrazino-7-beta-d-ribofuranosyl-7H-pyrrolo-(2, 3-d)-pyrimidine-5-carboxamide, NSC 188491) for 24 hours. ATC code:---
Control untreated MCF-7 cell sample
MCF-7 cells untreated.

sangivamycin study 1 / untreated MCF-7 cell sample

Relative Expression (log2-ratio):5.2624273
Number of Samples:2 / 2
Experimental sangivamycin study 1
MCF7 cells treated with 2uM sangivamycin for 24 hours. ATC code:---
Control untreated MCF-7 cell sample
MCF-7 cells untreated.

sapphyrin PCI-2050 study 1 / mannitol treated A549 cell sample

Relative Expression (log2-ratio):4.2784185
Number of Samples:3 / 3
Experimental sapphyrin PCI-2050 study 1
A549 human lung cancer cells were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, 1.25uM sapphyrin PCI-2050 (1.25uM final concentration) was added to the culture. ATC code:---
Control mannitol treated A549 cell sample
A549 human lung cancer cells were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, mannitol (5% final concentration) was added to the culture.

sapphyrin PCI-2050 study 2 / mannitol treated A549 cell sample

Relative Expression (log2-ratio):4.0728884
Number of Samples:2 / 3
Experimental sapphyrin PCI-2050 study 2
A549 human lung cancer cells were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, 2.5uM sapphyrin PCI-2050 (final concentration) was added to the culture. ATC code:---
Control mannitol treated A549 cell sample
A549 human lung cancer cells were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, mannitol (5% final concentration) was added to the culture.

stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)

Relative Expression (log2-ratio):4.0261965
Number of Samples:3 / 4
Experimental stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast)
Proerythroblast differentiated from IRF2 (interferon regulatory factor 2) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF2 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.
Control stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.

stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)

Relative Expression (log2-ratio):3.7632685
Number of Samples:3 / 4
Experimental stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast)
Proerythroblast differentiated from IRF6 (interferon regulatory factor 6) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF6 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.
Control stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.

atopic dermatitis study 21 (non-lesional; whole skin) / normal skin tissue

Relative Expression (log2-ratio):3.0463839
Number of Samples:5 / 6
Experimental atopic dermatitis study 21 (non-lesional; whole skin)
Non-lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %.
Control normal skin tissue
Full thickness skin samples isolated from healthy subjects by laser capture microdissection.

atopic dermatitis study 21 (lesional; whole skin) / normal skin tissue

Relative Expression (log2-ratio):2.8451605
Number of Samples:5 / 6
Experimental atopic dermatitis study 21 (lesional; whole skin)
Lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %.
Control normal skin tissue
Full thickness skin samples isolated from healthy subjects by laser capture microdissection.

ovarian tumor study 17 / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):2.7341747
Number of Samples:9 / 10
Experimental ovarian tumor study 17
Human epithelial tumor cell samples from the ovary of patients with primary clear cell carcinoma. Samples were derived by laser capture microdissection (LCM).
Control normal ovarian surface epithelial cell sample
Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue from donors with non-cancerous, benign gynecological diseases.

medulloblastoma study 2 / non-tumor brain tissue

Relative Expression (log2-ratio):-2.6418686
Number of Samples:4 / 9
Experimental medulloblastoma study 2
Primary tumor tissue sample from the infratentorial brain of pediatric patients with large-cell anaplastic medulloblastoma.
Control non-tumor brain tissue
Histologically normal brain tissue at rapid autopsy from patients who died from atypical teratoid/rhabdoid tumor.